MEDIVIR, INTERIM REPORT, 1 January – 30 September 2005

• A phase IIa study on MIV-210 against multiresistant HIV began in September. • A Candidate drug (CD) was designated on the Cathepsin K project against osteoporosis in May. • BI (Boehringer Ingelheim) concluded its research collaboration with Medivir on the HIV compound MIV-310 (polymerase inhibitor) in March. Medivir has decided to prioritize its protease projects, and accordingly, will not assign in-house resources to MIV-310 until further notice. • Consolidated net sales were SEK 41.0 (18.4) m in the period. • The loss after tax was SEK -112.6 (-132.3) m; earnings per share were SEK -8.72 (-12.31). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Financial Statement will be published on 16 February 2006 The Three-month Interim Report will be published on 26 April 2006 The Annual General Meeting will be on 26 April 2006, from 3 p.m. Medivir’s financial reports are available from its Website, from these dates.

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links